KRM AYURVEDA LTD

(Formerly Known as KRM Ayurveda Private Limited)

SYMBOL: KRMAYURVED

14th November, 2026

To
The Manager
Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra East Mumbai- 400 051

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release on Unaudited Financial Results for the Quarter & Half Year ended September 30, 2026 (Q2 & H1 FY27).

Dear Sir/Ma'am,

Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release titled **"Q2 & H1 FY27 – Key Financial Highlights"** being issued by KRM Ayurveda Limited, highlighting the Company's unaudited financial performance for the half year ended September 30, 2026 (Q2 & H1 FY27), along with key business and operational updates.

You are requested to kindly take the above information and the enclosed Press Release on record.

Thank you,

For KRM Ayurveda Limited
(Formerly known as KRM Ayurveda Private Limited)

Sanchit Hans

Digitally signed by Sanchit Hans
DN: c=IN, o=Personal, title=4238, pseudonym=vk1secyz0afnwli2phd6omj5g4397rbq, 2.5.4.20=c0df36d49ddd8f31d92ebc4329cfdfa9997c4a9e8ae6f7e0975fbb7e14bd6b24, postalCode=110034, st=Delhi, serialNumber=109c663521e9a1028142f4a7fdde7a52964ebed867f51cf4b4f987e023c2f17f, cn=Sanchit Hans
Date: 2026.11.14 17:14:44 +05'30'

Sanchit Hans
Whole-Time Director
DIN: 09228549

Encl: a/a

Regd. Off. : A-16, G.T. KARNAL ROAD, INDUSTRIAL AREA, NORTH WEST DELHI-110033
Website: www.krmayurveda.com
Email: hrhead@krmayurveda.com
account1@krmayurveda.com
Contact: +91-9667791365
CIN: L24239DL2019PLC354658

KRM Ayurveda Scales New Growth Milestones in H1 FY27,
Revenue Rises 40% | EBITDA Jumps 80% | PAT Soars 110%,
Margins Expand Significantly, Strengthening Growth Momentum

Delhi, November 13, 2026:

KRM Ayurveda Limited (NSE: KRMAYURVED), an integrated Ayurvedic healthcare company, has reported its unaudited financial results for Q2 and H1 FY27, reflecting its operational and financial performance during the period.

Financial Performance Highlights

Q2 FY27 vs Q2 FY26

Particulars (₹ Lakhs)	Q2 FY27	Q2 FY26	YoY Change
Total Income	3,529.95	2,383.80	+48.08% ↑
EBITDA	1,126.33	688.48	+63.60% ↑
EBITDA (%)	31.91%	28.88%	+302.62 BPS ↑
PAT	814.64	416.98	+95.37% ↑
PAT Margin (%)	23.08%	17.49%	+558.57 BPS ↑
EPS (₹)	3.83	2.69	+42.38% ↑

H1 FY27 vs H1 FY26

Particulars (₹ Lakhs)	H1 FY27	H1 FY26	YoY Change
Total Income	6,816.50	4,865.43	+40.10% ↑
EBITDA	2,382.40	1,324.92	+79.81% ↑
EBITDA (%)	34.95%	27.23%	+771.92 BPS ↑
PAT	1,723.09	822.27	+109.55% ↑
PAT Margin (%)	25.28%	16.90%	+837.80 BPS ↑
EPS (₹)	8.10	5.30	+52.83% ↑

Key Business Highlights

1. **Gurugram Expansion**

- New Ayurveda & Panchakarma hospital at Sector-47, Gurugram.
- Addition of 80 beds.
- Facility spread across 27,500 sq. ft.
- Existing 95-bed Sector-41 facility operating at approximately 90–100% capacity.

2. **Healthcare Network Expansion**

- MSS Hospital, Pitampura established with 23 beds.
- Facility spread across 5,631 sq. ft., offering both IPD and OPD services.
- Karma Ayurveda Day Care Centre, Janakpuri commenced operations in April 2026.
- Janakpuri facility spans approximately 2,760.90 sq. ft.
- New Karma Ayurveda Day Care Centre commenced operations in Vashi, Navi Mumbai, on 3 September 2026.
- Vashi facility spans approximately 2,100 sq. ft. and operates under a 5-year lease.

3. **NABH Accreditation**

- Bengaluru Panchakarma Day Care Centre received NABH accreditation, valid until May 2029.
- Panchakarma Day Care Centre at Dwarka, New Delhi, received NABH accreditation, valid until 20 August 2029.
- Panchakarma Day Care Centre at Patna, Bihar, received NABH accreditation, valid until 18 June 2029.
- Noida Panchakarma Day Care Centre received NABH accreditation, valid until 3 August 2029.
- Gomti Nagar, Lucknow Panchakarma Day Care Centre received NABH accreditation, valid until 20 July 2029.
- Accreditations follow assessments of infrastructure, clinical practices, patient-care protocols, quality management systems and operational processes.
- Strengthens the Company's focus on standardized clinical practices, patient safety, quality standards and operational excellence across its healthcare network.

4. **Nutraceuticals & Wellness**

- Acquired 100% stake in Karma Nutravedics Pvt. Ltd. for a consideration of ₹1 lakh.
- Subsidiary to focus on nutraceuticals, dietary and health supplements, and allied wellness products.
- Creates a dedicated platform for the Company's new growth vertical.
- No equity dilution for existing shareholders.

5. **Asset Optimisation**

- Entered into an Agreement to Sell for a non-operational property located at G.T. Karnal Road, New Delhi.
- Property measures approximately 392 sq. yards.
- Aggregate consideration of approximately ₹3.50 Crore.
- Supports efficient asset utilisation and disciplined capital allocation.

Management Commentary on The Q2 & H1 FY27 Performance & Key Business Updates

"Q2 and H1 FY27 mark a significant period of progress for KRM Ayurveda, reflecting the strength of our operating model and our continued focus on profitable growth. We have delivered a strong financial performance, with H1 FY27 Total Income growing by 40.10% year-on-year to ₹68.17 crore, while EBITDA increased by 79.81% to ₹23.82 crore. Most notably, Profit After Tax surged by 109.55% to ₹17.23 crore, more than doubling over the corresponding period last year.

What makes this performance particularly encouraging is the improvement in profitability alongside growth. Our EBITDA margin expanded by 772 basis points to 34.95%, while PAT margin improved by 838 basis points to 25.28%. The momentum was equally evident in Q2 FY27, with PAT registering a growth of 95.37% and EBITDA increasing by 63.60% year-on-year. This reflects our ability to translate business growth into stronger earnings and improved operating efficiency.

Beyond the financial performance, we continue to build the foundations for our next phase of expansion. Additional 80 bed Ayurveda and Panchakarma hospital at Sector-47, Gurugram, represents a significant addition to our healthcare infrastructure, particularly as our existing 95-bed Sector-41 facility continues to operate at approximately 90–100% capacity. Our expanding presence across Pitampura, Janakpuri, Vashi & Ghaziabad further strengthens our reach and accessibility across key markets.

Quality remains central to the way we scale. With NABH accreditations across our Panchakarma centres in Bengaluru, Dwarka, Patna, Noida and Lucknow, we are progressively strengthening standardized clinical practices, patient safety and institutional credibility across our network.

We are also broadening our business horizon through the acquisition of Karma Nutravedics Private Limited, creating a dedicated platform to enter the nutraceuticals, dietary supplements and allied wellness segments. At the same time, our proposed monetisation of a non-operational asset at G.T. Karnal Road reflects our focus on efficient capital allocation and better utilisation of resources.

As we move ahead, our focus is on building a more integrated Ayurvedic healthcare platform, combining hospitals, day-care centres, clinical expertise, wellness products and accessible healthcare solutions. We believe that the combination of strong financial performance, disciplined expansion and a broader wellness portfolio will position KRM Ayurveda to capture the growing opportunity in India's organised Ayurvedic healthcare market while maintaining our emphasis on sustainable and profitable growth."

~ Dr. Puneet Dhawan, MD & Promoter

About The Company

KRM Ayurveda Limited, established in 2019, is an integrated Ayurvedic healthcare company that combines authentic Ayurveda with modern healthcare practices. Originally founded as a kidney-specialty hospital, the Company has evolved into a multi-specialty Ayurvedic healthcare platform, with an expanding network of hospitals and clinics across multiple Indian cities. Its integrated offerings include holistic treatment solutions, tele-consultancy services, product manufacturing and D2C wellness solutions, supported by scalable digital healthcare initiatives to enhance patient reach and accessibility.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor	
AKMIL	*AKMIL Strategic Advisors Private Limited* *Mr. Milind Apte – Director* *milind@akmiladvisors.com* *+91 98209 41925* *www.akmiladvisors.com*